Neurontin (Gabapentin)

Gabapentin binds to the α2δ subunit of voltage‑gated calcium channels in the central nervous system. This binding limits calcium entry into neurons, decreasing the release of excitatory neurotransmitters and thereby reducing neuronal hyperexcitability that underlies seizures and neuropathic pain.

The appropriate dose of Neurontin is individualized by the prescribing clinician based on the patient’s condition, renal function, age and response to therapy. Dosage regimens may vary widely, and any adjustments should follow the prescriber’s instructions.

Safety data for gabapentin in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss these considerations with the patient before initiating therapy during pregnancy or while breastfeeding.

To request Neurontin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other neuropathic pain medications such as pregabalin or duloxetine, gabapentin has a distinct binding site on calcium channels and a generally favorable tolerability profile. Choice of therapy depends on individual patient factors, efficacy, side‑effect tolerance and cost considerations.

Neurontin should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid environments such as bathrooms.

Neurontin is taken orally, usually with or without food, as directed by the prescriber. The tablets (or capsules, if supplied) should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include severe allergic reactions, suicidal thoughts or behaviors, and acute respiratory depression, especially when combined with other central nervous system depressants. Patients should seek immediate medical attention if they experience rash, swelling, difficulty breathing, mood changes or excessive drowsiness.

Neurontin is contraindicated in individuals with known hypersensitivity to gabapentin or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric conditions, or those taking multiple CNS depressants without close monitoring.